Related Experiment Video

Updated: Aug 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy

H Ben-Bassat1

  • 1Israel National Skin Bank, Hadassah Medical Organization, Jerusalem. benbassat@md.huji.ac.il

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed

Insights

Protein tyrosine kinase (PTK) inhibitors, like AG-1571, show promise for treating psoriasis by targeting epidermal growth factor receptor (EGFR) signaling. This offers a novel therapeutic approach for this inflammatory skin disease.

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Uncontrolled protein tyrosine kinase (PTK) signaling drives proliferative and inflammatory diseases.
  • Psoriasis involves altered epidermal homeostasis, with evidence implicating the epidermal growth factor receptor (EGFR) system.

Purpose of the Study:

  • To summarize recent advancements in developing PTK inhibitors for psoriasis treatment.
  • To highlight the potential of targeting specific PTKs for selective therapeutic agents.

Main Methods:

  • Review of studies on PTK inhibitors, specifically AG-1571 (a tyrphostin derivative).
  • Evaluation of AG-1571's efficacy in inhibiting psoriatic keratinocyte proliferation and EGFR kinase activity.
  • Consideration of newly developed in vivo psoriasis models for drug evaluation.

Main Results:

  • AG-1571 potently inhibits psoriatic keratinocyte proliferation.
  • Inhibitory activity of AG-1571 strongly correlates with its EGFR kinase inhibitory activity.
  • AG-1571 has undergone clinical trials.

Conclusions:

  • PTK inhibitors represent a promising therapeutic strategy for psoriasis.
  • Targeting EGFR with inhibitors like AG-1571 may offer a novel, specific treatment approach.
  • In vivo psoriasis models are valuable for evaluating PTK inhibitors.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...